Alimemazine Tartrate

Alimemazine Tartrate (CAS No.: 4330-99-8) is a synthetic phenothiazine derivative positioned in neuropharmacology and inflammation related discovery workflows as a small molecule GPCR active modulator with primary antagonist activity at histamine H1 receptors and reported interactions across additional aminergic receptor systems, including serotonergic, dopaminergic, adrenergic, and muscarinic pathways, thereby supporting its use as a reference chemotype for studying receptor cross reactivity, ligand bias, and network level signaling effects in complex cell systems; within biomedical research settings it is commonly categorized as an antipruritic and centrally active sedative class probe compound, and published preclinical observations further indicate antiemetic, antispasmodic, and antiviral associated bioactivity profiles alongside experimental findings suggestive of pancreatic beta cell supportive effects in mouse metabolic models, although mechanistic attribution for these latter observations remains to be fully resolved and should be interpreted as exploratory; because robust standardized potency datasets for this exact salt form are not uniformly reported across assay platforms, in vitro activity is generally treated as occurring from nanomolar to micromolar ranges consistent with phenothiazine class pharmacology depending on receptor subtype, cell context, and endpoint selection, and typical applications include receptor binding panels, signal transduction assays, neuronal or epithelial cell based phenotypic screens, and hypothesis driven in vivo pharmacology studies in rodents where the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives, making this compound suitable for mechanism oriented laboratory investigation and comparative lead profiling in nonclinical drug discovery research.